Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

H. Kim, Youn; Duvic, Madeleine; Obitz, Erik; Gniadecki, Robert; Iversen, Lars; Österborg, Anders; Whittaker, Sean; Illidge, Tim; Schwarz, Thomas; Kaufmann, Roland; D. Cooper, Kevin; Knudsen, Kim; Lisby, Steen; Baadsgaard, Ole; J. Knox, Susan

doi:10.1182/blood-2006-12-062877

Public

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Published in Blood • Feb 21, 2007

Authors:

Youn H. Kim

Madeleine Duvic

Erik Obitz

Abstract

The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two phase 2, multicenter, prospective, open-label, uncontrolled clinical studies. Patients with treatment refractory CD4(+) CTCL (mycosis fungoides [MF], n = 38; Sézary syndrome ...

Subject

Medicine

Mycosis fungoides

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!